Thursday, 17 Sep 2026
Empowering Chinese Pharma’s Global Expansion
Contact US
Home
About US
Policy Hub
Categories
Drug
Company
Deals
Policy / Regulatory
Medical Device
R&D
Legal / IP
Digital
Privacy Policy
Contact US
My News
Cancer
Clinical trial approval / initiation
Product approvals
Clinical trial results
Finance
ADC / XDC
Finanical Reports
Biotech
Market approval filings
PD-1/L1
Read History
Search
Pages
Home
Blog Index
POLICY HUB
Contact Us
Personalized
Read History
Categories
Company
Drug
Policy / Regulatory
Medical Device
R&D
Digital
Legal / IP
Deals
Have an existing account?
Sign In
Follow US
Fineline Cube
Follow:
14409
Articles
Company
Drug
Buchang Pharmaceuticals Gains NMPA Approval for BC008-1A Clinical Study
February 6, 2025
Company
Drug
CDE Prioritizes Review of Pearl Bio’s Breatinib for NSCLC Treatment
February 6, 2025
Company
Drug
Jiangsu Hengrui Medicine Gains NMPA Approval for HRS-6209 Clinical Study
February 6, 2025
Company
Drug
I-Mab’s Lemzoparlimab Gains CDE Approval for HR-MDS Phase III Trial
February 8, 2025
Company
Drug
Takeda’s Modakafusp Alfa and TAK-981 Gain NMPA Clinical Trial Approvals
February 8, 2025
Company
Drug
Huahai Pharmaceutical Gains FDA Approval for Generic Fingolimod
February 8, 2025
Company
Deals
Vathin Medical Instrument Raises Pre-Series B Funding Led by IDG Capital
February 8, 2025
Company
Policy / Regulatory
NMPA Issues Guidelines on Medical Device Grading Administration
February 8, 2025
Policy / Regulatory
Frontier Biotech’s FB2001 Inhalant Accepted for NMPA Review
February 9, 2025
Company
Drug
Luye Pharma’s LY03015 Receives FDA Approval for Phase I Clinical Study
February 9, 2025
Company
Deals
Hengrui Medicine to Incentivize Employees with Share Distribution
February 9, 2025
Policy / Regulatory
Biden’s Executive Order Boosts US Bio-Economy, Targets China’s Biotech Rise
February 9, 2025
1
2
…
1,133
1,134
1,135
1,136
1,137
…
1,200
1,201
Welcome to Fineline Cube!
Username or Email Address
Password
Remember me
Lost your password?